{"id":"ibuprofen-echog","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Dyspepsia"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL521","moleculeType":"Small molecule","molecularWeight":"206.28"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Like conventional ibuprofen, this formulation blocks COX-1 and COX-2 enzymes, thereby decreasing production of pro-inflammatory prostaglandins and providing analgesic, anti-inflammatory, and antipyretic effects. The 'EchoG' designation likely refers to a specific formulation, delivery mechanism, or imaging-related variant under investigation by the Spanish research foundation, though the core mechanism remains NSAID-based inhibition of prostaglandin synthesis.","oneSentence":"Ibuprofen EchoG is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:16:51.733Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pain and inflammation (specific Phase 3 indication unclear from available data)"}]},"trialDetails":[{"nctId":"NCT04282941","phase":"PHASE3","title":"Clinical Trial to Evaluate Two Guidelines for the Administration of Ibuprofen in the Treatment of Persistent Ductus Arteriosus Eco-guided: Impact in the Intestinal Prognosis","status":"UNKNOWN","sponsor":"Instituto de Investigación Hospital Universitario La Paz","startDate":"2017-02-20","conditions":"Persistent Ductus Arteriosus","enrollment":180},{"nctId":"NCT01593163","phase":"PHASE3","title":"Echocardiographically Guided Versus Standard Ibuprofen Treatment for Patent Ductus Arteriosus","status":"COMPLETED","sponsor":"Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz","startDate":"2009-05","conditions":"Patent Ductus Arteriosus","enrollment":49}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Echocardiographically guided ibuprofen treatment"],"phase":"phase_3","status":"active","brandName":"Ibuprofen EchoG","genericName":"Ibuprofen EchoG","companyName":"Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz","companyId":"fundacion-para-la-investigacion-biomedica-del-hospital-universitario-la-paz","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ibuprofen EchoG is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation. Used for Pain and inflammation (specific Phase 3 indication unclear from available data).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}